Research map: Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

Back to the article

Papers in this map

  1. Constructing Inverse Probability Weights for Marginal Structural Models · Stephen R. Cole · 2008 · 2818 citations · Cited by this paper
  2. Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan · 2026 · Related
  3. Pemphigus · Michael Kasperkiewicz · 2017 · 524 citations · Cited by this paper
  4. HPV29 ‐Associated Periungual Epidermoid/Verrucous Cyst · 2026 · Related
  5. Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity · Víctor H. Engelhard · 2018 · 238 citations · Cited by this paper
  6. IL ‐17 Signaling Inhibitors in Localized Scleroderma: A Single‐Center Case Series of Nine Patients · 2026 · Related
  7. Cloning and functional expression of the T cell activation antigen CD26 · Toshiaki Tanaka · 1992 · 181 citations · Cited by this paper
  8. Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study · 2026 · Related
  9. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland · Michael Benzaquen · 2017 · 159 citations · Cited by this paper
  10. Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan · 2026 · Related
  11. An Updated Review of Pemphigus Diseases · Ali M. Malik · 2021 · 131 citations · Cited by this paper
  12. Claudin‐3 Deficiency Potentially Permits Epidermal Nerve Infiltration and Contributes to Sensitive Skin Pathophysiology · 2026 · Related
  13. Geoepidemiologic considerations of auto-immune pemphigus · Nicolás Meyer · 2009 · 127 citations · Cited by this paper
  14. Wound, Pressure Ulcer, and Burn Guidelines (2023)‐6: Guidelines for the Management of Burns, Third Edition · 2026 · Related
  15. Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo · Ulf Forssmann · 2008 · 115 citations · Cited by this paper
  16. Mosaic RASopathy Caused by a Somatic HRAS p. Gly12Ser Variant in a Patient With Malignant Melanoma · 2026 · Related
  17. Malignancies in Pemphigus and Pemphigoid Diseases · Franziska Sophie Schulze · 2015 · 110 citations · Cited by this paper
  18. Giant Hypertrichotic Pigmented Neurofibroma Mimicking Giant Congenital Melanocytic Nevus in Neurofibromatosis Type 1: A Rare Case Report · 2026 · Related
  19. Association Between Medication Use and Bullous Pemphigoid · Sian-De Liu · 2020 · 108 citations · Cited by this paper
  20. Preserved Foot Function After Repeated Surgical Intervention in Recessive Dystrophic Epidermolysis Bullosa: A 17‐Year Follow‐Up · 2026 · Related
  21. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens · Lucia C. Petito · 2020 · 96 citations · Cited by this paper
  22. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes · A. Parameswaran · 2014 · 77 citations · Cited by this paper
  23. Autoreactive B Cell Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus Lesions · Shengru Zhou · 2019 · 73 citations · Cited by this paper
  24. KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes · Titli Nargis · 2017 · 63 citations · Cited by this paper
  25. Kallikrein-5 Promotes Cleavage of Desmoglein-1 and Loss of Cell-Cell Cohesion in Oral Squamous Cell Carcinoma · Rong Jiang · 2010 · 59 citations · Cited by this paper
  26. Dipeptidyl-peptidase IV inhibitor–associated bullous pemphigoid: A systematic review and meta-analysis · Khalaf Kridin · 2018 · 53 citations · Cited by this paper
  27. Dipeptidyl peptidase‐4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta‐analysis · Kevin H. Phan · 2019 · 39 citations · Cited by this paper
  28. Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials · Wenjia Yang · 2020 · 30 citations · Cited by this paper
  29. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study · Chen‐Yi Wu · 2020 · 28 citations · Cited by this paper
  30. Association Between Pemphigus and Neurologic Diseases · Khalaf Kridin · 2018 · 26 citations · Cited by this paper
  31. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase–4 Inhibitor vs Second-generation Sulfonylurea · Hemin Lee · 2020 · 26 citations · Cited by this paper
  32. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study · Jiayin Guo · 2019 · 18 citations · Cited by this paper
  33. Firth's penalized method in Cox proportional hazard framework for developing predictive models for sparse or heavily censored survival data · Avizit Chandra Adhikary · 2020 · 13 citations · Cited by this paper
  34. Development of pemphigus vulgaris during treatment with dipeptidyl peptidase‐4 inhibitors: a case report · Kazumasa Oya · 2021 · 4 citations · Cited by this paper
  35. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Chronic Inflammatory Skin Diseases in Type 2 Diabetes Mellitus in Taiwan: A Nationwide Population-Based Cohort Study · Hsien‐Yi Chiu · 2024 · 2 citations · Cited by this paper
  36. Characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated pemphigus patients: A retrospective analysis of 66 cases · Gaurav Nitin Pathak · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)